By Jeanne Loring There are ten million people in the world who have Parkinson’s disease. 125,000 of these are living in California. People with the disease often have to step away from their jobs because the main symptoms – tremor or freezing up of muscles – make it difficult to get through a whole day […]
On the threshold of cell therapy for Parkinson’s disease Read More »
New human clinical trials using derivatives of pluripotent stem cells in China for Parkinson’s Disease (PD) have raised expectations and some eyebrows. PD is a neurodegenerative condition, sometimes diagnosed or followed by PET scans such as the one at left, characterized by loss of dopaminergic neurons leading to severe and sometimes life-threatening symptoms. Pluripotent stem
How risky are stem cell trials for Parkinson’s beginning in China? Read More »
What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from
Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »
Clinicaltrials.gov is where you want to go for finding a certain clinical trial and studies. Note that this U.S. database Clinicaltrials.gov includes international trials. It is a very powerful tool! Check it out here to do your own searches. Also follow me on Twitter for all the latest info and expert analysis: http://twitter.com/pknoepfler and this patient’s
Tool to easily search for a stem cell clinical trial for your disease Read More »
What are pericytes? What about brain pericytes? How are they different than brain parasites? Pericytes on the brain Someone once asked me my favorite type of cell. As a cell biologist, I easily can’t pick just one. It’s like asking a parent to pick their favorite child. However, I will say that pericytes and microglia
The Japanese stem cell and regenerative medicine oversight system is different than here in the U.S. and in Europe. Japan has had a more permissive approach to overseeing regenerative medicine. While most of the attention has focused on fairly legitimate regenerative biotechs and other sponsors in Japan, there are unproven stem cell clinics there. These
Japanese stem cell clinic oversight: the case of MSC clinic Seijikai Fukuoka Read More »
Toward the end of each year I make predictions for the stem cell and regenerative medicine field for the coming year. I’ve been doing this for more than a dozen years in various forms. In this post I’m looking at the (gene-edited, stemness enriched) tea leaves for 2025 for the regenerative arena. These predictions include
25 stem cell & regenerative medicine predictions for 2025 Read More »
What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice
Poll on stem cell & regenerative medicine good news of 2024 Read More »
Mesenchymal stromal/stem cells or MSCs are widely used by unproven clinics, but MSC research also suggests real promise in specific areas. Clinics mainly use adipose MSCs (often called SVF) or bone marrow MSCs. However, umbilical cord MSC preparations are getting more popular too. Many questions swirl around the use of MSCs including what exactly are
Looking for some stem cell good news? You’ll like today’s post. One mission of this blog The Niche is to promote rigorous science-based regenerative medicine, which can lead to investigating and writing about not-so-upbeat stuff. Risky clinics. People getting hurt. Patient lawsuits. Serious FDA, FTC, or state AG regulatory developments. Such actions can be good
Recent stem cell & regenerative medicine good news Read More »